Meeting
2016 ASCO Annual Meeting
Phase 2 study of the safety and efficacy of pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for advanced melanoma (KEYNOTE-022).
Authors
Georgina V. Long
Melanoma Institute Australia, The University of Sydney, Mater Hospital, and Royal North Shore Hospital, North Sydney, NSW, Australia
Georgina V. Long , Omid Hamid , F. Stephen Hodi , Donald P. Lawrence , Victoria Atkinson , Alexander Starodub , Matteo S. Carlino , Rosalie Anne Fisher , Wilson H Miller , Michele Maio , Marcus Butler , Paola Queirolo , Pier Francesco Ferrucci , Teresa M. Petrella , Jacob Schachter , Yingjie Huang , Scott J. Diede , Scot Ebbinghaus , Antoni Ribas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02130466
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS9596)
DOI
10.1200/JCO.2016.34.15_suppl.TPS9596
Abstract #
TPS9596
Poster Bd #
198b
Abstract Disclosures
Similar Posters
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I.
First Author: Georgina V. Long
Poster
2019 ASCO Annual Meeting
The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i.
First Author: Georgina V. Long
Poster
2022 ASCO Annual Meeting
Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naïve patients with advanced non–small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study.
First Author: Tony S. K. Mok
Poster
2021 ASCO Annual Meeting
A phase 2 clinical trial on trametinib and low-dose dabrafenib in advanced pretreated BRAFV600/NRASQ61R/K/L wild-type melanoma (TraMel-WT): Interim efficacy and safety results.
First Author: Gil Awada